Gejl and colleagues demonstrated via FDG-PET-MRI that treatment with GLP-1 analogues restores glucose transport at the blood–brain barrier, which is typically impaired in AD patients (Gejl et al. 2017). This evidence concerns the gene GLP1R and Alzheimer disease.